I think our team is likely highly prepared to meet demand that will catapult sales well into record books for a new blockbuster drug. There are some drugs that are authorized to treat Covid-ish patients, and now sotrovimab, that is focused on end-stage treatment. That drug's authorization actually causes me to devalue the prospects for leronlimab.
I am going to be interested in seeing how these vaccines that can potentially change human cell structure or DNA sequencing, may affect the body's immune response system.
Market Data 
Markets 
